Legacy Trust Incyte Corp Transaction History

Legacy Trust

$408 Billion
Q2 2025

A detailed history of Legacy Trust transactions in Incyte Corp stock. As of the latest transaction made, Legacy Trust holds 36,116 shares of INCY stock, worth $2.95 Million. This represents 0.6% of its overall portfolio holdings.

Number of Shares

36,116

Previous 50,231 28.1%

Holding current value

$2.95 Million

Previous $3.04 Billion 19.13%

% of portfolio

0.6%

Previous 0.73%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 22, 2025	SELL	$55.17 - $71.22 $778,724 - $1.01 Million	-14,115 Reduced 28.1%	36,116 $2.46 Billion
Q1 2025 Apr 16, 2025	BUY	$60.0 - $75.26 $46,800 - $58,702	780 Added 1.58%	50,231 $3.04 Billion
Q4 2024 Jan 23, 2025	BUY	$65.08 - $83.38 $98,335 - $125,987	1,511 Added 3.15%	49,451 $3.42 Billion
Q3 2024 Oct 29, 2024	BUY	$57.33 - $68.61 $187,583 - $224,491	3,272 Added 7.33%	47,940 $3.17 Billion
Q2 2024 Jul 16, 2024	BUY	$51.18 - $63.75 $397,617 - $495,273	7,769 Added 21.05%	44,668 $2.71 Billion
Q1 2024 Apr 23, 2024	BUY	$56.55 - $66.59 $440,128 - $518,269	7,783 Added 26.73%	36,899 $2.1 Billion
Q4 2023 Jan 24, 2024	SELL	$52.16 - $64.19 $1.28 Million - $1.57 Million	-24,472 Reduced 45.67%	29,116 $1.83 Billion
Q3 2023 Oct 16, 2023	BUY	$57.77 - $65.93 $55,054 - $62,831	953 Added 1.81%	53,588 $3.1 Billion
Q2 2023 Aug 08, 2023	SELL	$60.95 - $75.51 $214,970 - $266,323	-3,527 Reduced 6.28%	52,635 $3.28 Billion
Q1 2023 Apr 19, 2023	SELL	$70.23 - $86.01 $15,450 - $18,922	-220 Reduced 0.39%	56,162 $4.06 Billion
Q4 2022 Apr 03, 2023	BUY	$67.18 - $84.11 $3.79 Million - $4.74 Million	56,382 New	56,382 $4.53 Billion

Others Institutions Holding INCY

# of Institutions

711

Shares Held

196M

Call Options Held

564K

Put Options Held

317K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $18.2B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legacy Trust, based on Form 13F filings with the SEC.

News

Stay updated on Legacy Trust with notifications on news.

Account